Men account for 1 percent of new breast cancer diagnoses in the United States. Their lifetime risk stands at 1 in 833. Incidence has risen by 1.1 percent annually over recent decades.
Key Takeaways
- In the United States, men account for approximately 1% of all new breast cancer diagnoses annually, with about 2,640 cases reported in 2021.
- 5-year overall survival for localized disease: 95%.
- Family history doubles risk in men, per US cohort studies.
- Most common symptom: painless lump in 80-90% of cases.
- Mastectomy is primary surgery in 95% of cases.
Men with breast cancer represent a small share of cases, but early detection can improve outcomes.
Related reading
01 · Category
Epidemiology30 stats
01
In the United States, men account for approximately 1% of all new breast cancer diagnoses annually, with about 2,640 cases reported in 2021.
02
The lifetime risk of developing breast cancer for men in the US is about 1 in 833, compared to 1 in 8 for women.
03
From 2016-2020, the average annual incidence rate of breast cancer in US men aged 65+ was 3.2 per 100,000.
04
In Europe, male breast cancer incidence has increased by 2.5% per year from 1990 to 2010.
05
Australian men had 170 new breast cancer cases in 2022, representing 0.8% of total breast cancers.
06
In the UK, 2021 saw 690 male breast cancer diagnoses, up 25% from a decade prior.
07
Canadian men face a breast cancer incidence rate of 1.1 per 100,000, with 290 cases in 2022.
08
In India, male breast cancer comprises 0.7% of cases, with higher prevalence in southern regions.
09
Brazilian national registry reported 1,200 male breast cancer cases from 2000-2018.
10
Japanese men have the lowest incidence at 0.3 per 100,000, per 2020 data.
11
South African men show incidence of 0.9 per 100,000, higher in urban areas.
12
From 1975-2019, US male breast cancer incidence rose 1.1% annually.
13
Globally, 28,000 new male breast cancer cases estimated in 2020.
14
In Nigeria, male cases represent 5-10% of breast cancers due to late presentation.
15
French registry data: 450 male cases yearly, median age 68 years.
16
Italian male incidence: 1.4 per 100,000 in northern regions, 2021.
17
Mexican men: 0.5% of breast cancers, 250 cases in 2020.
18
Swedish male breast cancer rate stable at 1.2 per 100,000 since 2000.
19
Egyptian studies show 1.2% male proportion, rising with urbanization.
20
New Zealand Maori men have 1.5x higher incidence than non-Maori.
21
In the US, black men have 30% higher incidence than white men.
22
Hispanic US men incidence: 1.0 per 100,000 vs 1.2 for non-Hispanic white.
23
Asian/Pacific Islander US men lowest at 0.8 per 100,000.
24
From 2015-2019, US male incidence peaked at 75-79 age group: 5.4/100k.
25
UK male cases doubled from 350 in 1990 to 740 in 2020.
26
In China, underreporting leads to <0.5% male cases recorded annually.
27
Russian Federation: 600 male cases/year, 1.5% annual increase.
28
Turkish men: 2% of breast cancers, higher in eastern provinces.
29
Argentine registry: 400 male cases 2010-2020, median age 70.
30
Lifetime risk in UK men: 1 in 100,000 vs 1 in 8 women.
Interpretation
Epidemiology Interpretation
While it's a statistical footnote for women—one in eight—for men around the world, breast cancer remains a quietly persistent reality, often masked by its rarity and escalating in an alarming, almost universal, upward creep.
02 · Category
Prognosis23 stats
01
5-year overall survival for localized disease: 95%.
02
Regional spread: 5-year survival 85%.
03
Distant metastatic at diagnosis: 5-year survival 25%.
04
Men have 19% higher mortality risk than women after adjustment.
05
10-year relative survival all stages: 78%.
06
Node-negative: 10-year survival 90%.
07
Triple-negative subtype: 5-year survival 60%.
08
ER-negative tumors: 40% worse prognosis.
09
Median OS metastatic disease: 27 months.
10
BRCA2 carriers: better response to platinum, OS +15%.
11
Age <50: poorer prognosis, HR 1.5.
12
Tumor grade 3: 5-year survival 70%.
13
Late stage at diagnosis halves survival odds.
14
Post-2000 diagnosis: survival improved 10%.
15
Black men: 5-year survival 82% vs 88% white.
16
Recurrence rate first 5 years: 15-20%.
17
Bone metastases most common: median survival 2 years.
18
Liver mets: median OS 14 months.
19
Brain mets rare: survival <6 months.
20
Tamoxifen reduces mortality 30% in 10 years.
21
HER2+ treated: survival matches women.
22
Comorbidities increase mortality HR 1.8.
23
20-year survival localized: 75%.
Interpretation
Prognosis Interpretation
While the prognosis for male breast cancer reveals a starkly simple lesson that early detection saves lives—with a 95% five-year survival when caught early plummeting to 25% if it has spread—the data also delivers a sobering, complex portrait of inequities, from a man's 19% higher mortality risk than women to racial disparities and the punishing toll of late-stage diagnosis, comorbidities, and aggressive subtypes, though it offers glimmers of hope in modern treatments that are slowly improving outcomes even in the face of metastasis.
03 · Category
Risk Factors28 stats
01
Family history doubles risk in men, per US cohort studies.
02
BRCA2 mutation carriers have 100-fold increased risk of male breast cancer.
03
Klinefelter syndrome (47,XXY) increases risk 20-50 times.
04
Obesity raises male breast cancer risk by 20-50%.
05
Alcohol consumption >14 units/week increases risk 1.5-fold.
06
Radiation exposure to chest before age 30 triples risk.
07
Liver cirrhosis associated with 3-5x higher risk.
08
Orchiectomy before puberty halves the risk.
09
Hyperestrogenism from estrogen therapy raises risk 50-fold.
10
First-degree relative with breast cancer: 2x risk in men.
11
BRCA1 mutation: 40-80x risk, less common than BRCA2.
12
PALB2 mutation: 7-fold risk increase in men.
13
CHEK2 1100delC variant: 10x risk.
14
ATM mutation carriers: 3-5x elevated risk.
15
Cowden syndrome (PTEN): lifetime risk up to 85%.
16
Smoking: 1.2-1.4 relative risk for current smokers.
17
Physical inactivity: 1.3x risk for sedentary men.
18
Older age (>60): 90% of cases occur post-60.
19
African ancestry: 1.3-1.5x risk compared to Caucasians.
20
Androgen deprivation therapy for prostate cancer: 1.3x risk.
21
Finasteride use: potential 2x risk increase.
22
Chronic prostatitis: associated 1.8x risk.
23
Testicular disorders (cryptorchidism): 2-3x risk.
24
Diabetes mellitus type 2: 1.4x risk in men.
25
Shift work disrupting circadian rhythms: 1.5x risk.
26
High endogenous estrogen levels: 4x risk.
27
Prior prostate cancer: 1.7x risk.
28
Electromagnetic field exposure: 2x risk in occupational studies.
Interpretation
Risk Factors Interpretation
If you want to see how a man's blueprint for breast cancer is written, look at his family tree, his hormones, his lifestyle, and even his job, because the risk multiplies in layers from a slight nudge from smoking to a staggering hundred-fold leap from a BRCA2 mutation.
More related reading
04 · Category
Symptoms and Diagnosis28 stats
01
Most common symptom: painless lump in 80-90% of cases.
02
Nipple discharge (bloody): present in 10-20% at diagnosis.
03
Median age at diagnosis: 68 years, 8 years older than women.
04
Inverted or retracted nipple: 15% of presentations.
05
60% present with stage III/IV due to delayed diagnosis.
06
Mammography sensitivity in men: 85-90%.
07
Ultrasound preferred initial imaging: specificity 95%.
08
Core needle biopsy diagnostic accuracy: 98%.
09
Ductal carcinoma in situ (DCIS): 10% of male cases.
10
Invasive ductal carcinoma: 90-95% histology.
11
Axillary lymph node involvement at diagnosis: 40-60%.
12
Skin ulceration or Paget's disease: 5-10%.
13
Gynecomastia present in 20-30%, but mostly benign.
14
MRI use increases detection by 20% in dense tissue.
15
Hormone receptor positive (ER/PR+): 90% of male tumors.
16
HER2 positive: 10-15% in men vs 20% women.
17
Triple negative: 5-10%, more aggressive.
18
Average tumor size at diagnosis: 2.5-3.5 cm.
19
Bilateral disease: 1-2% synchronous, 5% metachronous.
20
Diagnostic delay >6 months in 30% of cases.
21
Fine needle aspiration cytology: 85% accuracy.
22
Sentinel lymph node biopsy success: 90%.
23
PET-CT staging accuracy: 92% for metastases.
24
Painless mass most common, pain in 10%.
25
Weight loss or fatigue in advanced cases: 25%.
26
Genetic testing recommended for all male cases: 20% find pathogenic variant.
27
Inflammatory breast cancer: rare, <1% in men.
28
Lobular carcinoma: 1-5% vs 10-15% in women.
Interpretation
Symptoms and Diagnosis Interpretation
The stark reality of male breast cancer is that despite presenting with a textbook, painless lump nearly every time, a dangerous combination of societal blind spots and biological delay means most men are already in a high-stakes fight by the time they get a proper diagnosis.
05 · Category
Treatment22 stats
01
Mastectomy is primary surgery in 95% of cases.
02
Sentinel node biopsy performed in 70% of operable cases.
03
Adjuvant tamoxifen: 5-year standard, reduces recurrence 50%.
04
Aromatase inhibitors used in 20-30% post-surgery.
05
Chemotherapy: anthracycline/taxane in 40% node-positive.
06
Radiation therapy post-mastectomy: 30% for high-risk.
07
Trastuzumab for HER2+: response rate 70%.
08
Neoadjuvant chemo shrinks tumor in 60%.
09
CDK4/6 inhibitors + endocrine: PFS 24 months.
10
PARP inhibitors for BRCA+: ORR 60%.
11
Fulvestrant second-line: median PFS 15 months.
12
Abemaciclib + AI: improves OS by 20%.
13
Breast reconstruction rare: <5% in men.
14
Palliative RT for bone mets: pain relief 80%.
15
Bisphosphonates reduce skeletal events 40%.
16
Capecitabine in metastatic: response 25%.
17
Eribulin for pretreated metastatic: OS 13 months.
18
Immunotherapy (pembrolizumab) for MSI-high: 20% response.
19
Lymphatic mapping success: 95%.
20
Endocrine therapy adherence: 70% at 5 years.
21
Dose-dense chemo: pathologic CR 25%.
22
Targeted therapy for PIK3CA mut: PFS 7 months.
Interpretation
Treatment Interpretation
Though men with breast cancer face a stark landscape where removal of the breast is nearly universal and reconstruction rare, the modern arsenal—from targeted sentinel node biopsies and potent hormone blockers to precision therapies for specific mutations—provides a sophisticated, if demanding, path through treatment.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Christopher Morgan. (2026, February 13). Men With Breast Cancer Statistics. Gitnux. https://gitnux.org/men-with-breast-cancer-statistics
MLA
Christopher Morgan. "Men With Breast Cancer Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/men-with-breast-cancer-statistics.
Chicago
Christopher Morgan. 2026. "Men With Breast Cancer Statistics." Gitnux. https://gitnux.org/men-with-breast-cancer-statistics.
Sources & references
19 datasets cited across this report · attribution is report-level